Inclusion of Adolescents in Adult Clinical Trials: Report of the Institute for Advanced Clinical Trials for Children’s Pediatric Innovation Research Forum

被引:0
作者
Gary J. Noel
Robert M. Nelson
Christina Bucci-Rechtweg
Ronald Portman
Thomas Miller
Dionna J. Green
Donna Snyder
Carmen Moreno
Collin Hovinga
Edward Connor
机构
[1] The Institute for Advanced Clinical Trials for Children,Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine
[2] Weill-Cornell Medical College,undefined
[3] Johnson & Johnson,undefined
[4] Novartis Pharmaceuticals Corporation,undefined
[5] Bayer US,undefined
[6] US Food and Drug Administration,undefined
[7] Universidad Complutense,undefined
[8] IiSGM,undefined
[9] CIBERSAM,undefined
[10] George Washington School of Medicine,undefined
来源
Therapeutic Innovation & Regulatory Science | 2021年 / 55卷
关键词
Pediatrics; Clinical trials; Adolescents; Drug development; Phase 3 trials;
D O I
暂无
中图分类号
学科分类号
摘要
Including adolescents in adult clinical trials can play an important role in making innovative new medicines available to children in a timelier fashion. Stakeholders involved in the processes leading to regulatory approval and labeling of new drugs recognize that challenges exist in involving adolescents and older children in clinical trials before the safety and efficacy of these drugs are established for adults. However, it has been possible to design and execute phase 3 trials that combine adults with adolescents which are medically and scientifically sound and ethically justified. Based on this experience and considerations of the medical and scientific, ethical, and operation-related matters, the 2019 Pediatric Innovation Research Forum advocated for the position that adolescents routinely be considered for enrollment in phase 3 clinical trials. The Forum also concluded that exclusion of adolescents in adult pivotal trials occur only when a thorough evaluation of the target disease and the potential benefit and risks of the study intervention supports a delay in their involvement until after completion of clinical trials in adults.
引用
收藏
页码:773 / 778
页数:5
相关论文
共 47 条
[1]  
Carmack M(2020)Pediatric drug policies supporting safe and effective use of therapeutics in children: a systemic analysis Health Aff 39 1799-1805
[2]  
Hwang T(2016)Children with multiple sclerosis should not become therapeutic hostages Ther Adv Neurol Disord 9 389-905
[3]  
Bourgrois FT(2018)Pediatric drug development: outlook for science based innovation Clin Pharm Therapeut 103 376-378
[4]  
Rose K(2017)Clinical research participation among adolescent and young adults at an NCI-designated comprehensive cancer center and affiliated hospital Support Care Cancer 25 1579-1586
[5]  
Miller T(2017)Adult-onset Nieman-pick disease type C: rapid treatment initiation advised but early diagnosis remains difficult Front Neurol 8 108-202
[6]  
Green DJ(2011)Adult-onset Pompe disease Acta Myol 30 200-e1249
[7]  
Zineh I(2011)Extrapolation of adult data and other data in pediatric drug-development programs Pediatrics 128 e1242-932
[8]  
Burckhart GJ(2013)Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007 JAMA Pediatr 167 926-4799
[9]  
Sanford DS(2010)Clinical pharmacology in the adolescent oncology patient J Clin Oncol 28 4790-211
[10]  
Beaumont JL(2008)The problems in scaling adult drug doses to children Arch Dis Child 93 207-771